drugset
Drugs / HPV-16 vaccine
last change Oct 2012 re-read 3 minutes ago

HPV-16 vaccine

Vaccine

Developed for
head and neck squamous cell carcinoma
Investigated by
National Institute of Dental and Craniofacial Research (NIDCR) · University of Maryland, Baltimore

Trials 1

today NCT00257738 · Ph 1
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT00257738 Nov 2005 → Oct 2012 head and neck squamous cell carcinoma University of Maryland, Baltimore Completed No outcome recorded

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as HPV-16 vaccine ClinicalTrials.gov intervention name — accepted as the source's own label NCT00257738 ↗
Modality Vaccine “MAGE-A3/HPV 16 Vaccine” NCT00257738 ↗
Route Subcutaneous “Administered Subcutaneously” NCT00257738 ↗